The effect of empagliflozin 10 mg in the correction of hyponatremia

Investigating the effect of empagliflozin 10 mg in correcting hyponatremia in chronic heart failure patients

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20191104045328N28

Enrollment

194

Registered

2024-09-12

Start date

2024-09-12

Completion date

Unknown

Last updated

2024-09-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic heart failure. Hypo-osmolality and hyponatremia

Interventions

Intervention 1: Control group: Patients in the placebo group will take a tablet similar to empagliflozin made of starch for 4 days. Intervention 2: Intervention group: Patients in the intervention gro

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients with chronic heart failure admitted to Amir al-Momenin (AS) hospital in Arak Having informed consent Glomerular filtration rate above 25 Stage 2 and 3 chronic heart failure

Exclusion criteria

Exclusion criteria: Type 2 diabetes mellitus History of sensitivity to empagliflozin Urinary tract infection

Design outcomes

Primary

Measure	Time frame
Serum sodium level. Timepoint: Before the intervention and the second day after the intervention. Method of measurement: Laboratory.;Incidence of hypoglycemia. Timepoint: After the intervention. Method of measurement: Random blood sugar level.;Urinary tract infection. Timepoint: After the intervention. Method of measurement: Occurrence of symptoms of urinary infection and burning and urinary frequency and positive urine culture.;Systolic and diastolic blood pressure. Timepoint: Before the intervention, the first day, the second day and the fourth day. Method of measurement: Mercury sphygmomanometer.	—

Measure

Time frame

Serum sodium level. Timepoint: Before the intervention and the second day after the intervention. Method of measurement: Laboratory.;Incidence of hypoglycemia. Timepoint: After the intervention. Method of measurement: Random blood sugar level.;Urinary tract infection. Timepoint: After the intervention. Method of measurement: Occurrence of symptoms of urinary infection and burning and urinary frequency and positive urine culture.;Systolic and diastolic blood pressure. Timepoint: Before the intervention, the first day, the second day and the fourth day. Method of measurement: Mercury sphygmomanometer.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Alireza Ali Saeidi

Arak University of Medical Sciences

Alisaeedi@arakmu.ac.ir+98 86 3417 3601

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026